TY - JOUR
T1 - CXCL13 as biomarker for histological involvement in Sjögren’s Syndrome
AU - ESSENTIAL (EULAR Sjögren's Syndrome Study Group)
AU - HarmonicSS (H2020)
AU - Colafrancesco, Serena
AU - Priori, Roberta
AU - Smith, Charlotte
AU - Minniti, Antonina
AU - Iannizzotto, Valentina
AU - Pipi, Elena
AU - Lucchesi, Davide
AU - Pontarini, Elena
AU - Nayar, Saba
AU - Campos, Joana
AU - Arienzo, Francesca
AU - Fusconi, Massimo
AU - Cerbelli, Bruna
AU - Giordano, Carla
AU - Valesini, Guido
AU - Bombardieri, Michele
AU - Fisher, Benjamin
AU - Barone, Francesca
PY - 2020/1/1
Y1 - 2020/1/1
N2 - OBJECTIVES: SS is an autoimmune condition characterized by systemic B-cell activation, autoantibody production and ectopic germinal centres' formation within the salivary gland (SG). The extent of SG infiltrate has been proposed as a biomarker of disease severity. Plasma levels of CXCL13 correlate with germinal centres' activity in animal models and disease severity in SS, suggesting its potential use as a surrogate serum marker to monitor local B-cell activation. The aim of this study was to evaluate the potential role of CXCL13 as a biomarker of SG pathology in two independent SS cohorts. METHODS: 109 patients with SS were recruited at Sapienza University of Rome (Italy) (n = 60), or at Queen Elizabeth Hospital in Birmingham and Barts Health NHS Trust in London (n = 49). Both sera and matched minor SG biopsy were available. Sicca (n = 57) and healthy subjects' (n = 19) sera were used as control. RESULTS: CXCL13 serum level was higher in SS patients compared with controls. Correlations between its serum levels and a series of histomorphological parameters, including size of the aggregates and the presence germinal centres', were observed. CONCLUSION: Our data foster the use of CXCL13 to monitor the extent of local pathology in SS and its validation in longitudinal clinical studies.
AB - OBJECTIVES: SS is an autoimmune condition characterized by systemic B-cell activation, autoantibody production and ectopic germinal centres' formation within the salivary gland (SG). The extent of SG infiltrate has been proposed as a biomarker of disease severity. Plasma levels of CXCL13 correlate with germinal centres' activity in animal models and disease severity in SS, suggesting its potential use as a surrogate serum marker to monitor local B-cell activation. The aim of this study was to evaluate the potential role of CXCL13 as a biomarker of SG pathology in two independent SS cohorts. METHODS: 109 patients with SS were recruited at Sapienza University of Rome (Italy) (n = 60), or at Queen Elizabeth Hospital in Birmingham and Barts Health NHS Trust in London (n = 49). Both sera and matched minor SG biopsy were available. Sicca (n = 57) and healthy subjects' (n = 19) sera were used as control. RESULTS: CXCL13 serum level was higher in SS patients compared with controls. Correlations between its serum levels and a series of histomorphological parameters, including size of the aggregates and the presence germinal centres', were observed. CONCLUSION: Our data foster the use of CXCL13 to monitor the extent of local pathology in SS and its validation in longitudinal clinical studies.
KW - Sjögren’s syndrome
KW - biomarkers
KW - histopathology
KW - cytokines and inflammatory mediators
KW - lymphocytes
UR - http://www.scopus.com/inward/record.url?scp=85076449968&partnerID=8YFLogxK
U2 - 10.1093/rheumatology/kez255
DO - 10.1093/rheumatology/kez255
M3 - Article
SN - 1462-0324
VL - 59
SP - 165
EP - 170
JO - Rheumatology (Oxford, England)
JF - Rheumatology (Oxford, England)
IS - 1
ER -